{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:36:41Z","timestamp":1791229001625,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T00:00:00Z","timestamp":1294617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T00:00:00Z","timestamp":1294617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2011,4,14]]},"DOI":"10.1038\/onc.2010.554","type":"journal-article","created":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T11:19:57Z","timestamp":1294658397000},"page":"1822-1830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["PAX5\u2013PML acts as a dual dominant-negative form of both PAX5 and PML"],"prefix":"10.1038","volume":"30","author":[{"given":"S","family":"Kurahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,10]]},"reference":[{"key":"BFonc2010554_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.bbrc.2006.05.047","volume":"345","author":"A Atsumi","year":"2006","unstructured":"Atsumi A, Tomita A, Kiyoi H, Naoe T . (2006). Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun 345: 1471\u20131480.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2010554_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev.immunol.22.012703.104807","volume":"22","author":"M Busslinger","year":"2004","unstructured":"Busslinger M . (2004). Transcriptional control of early B cell development. Annu Rev Immunol 22: 55\u201379.","journal-title":"Annu Rev Immunol"},{"key":"BFonc2010554_CR3","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1073\/pnas.93.12.6129","volume":"93","author":"M Busslinger","year":"1996","unstructured":"Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z . (1996). Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci USA 93: 6129\u20136134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2010554_CR4","first-page":"3345","volume":"89","author":"GQ Chen","year":"1997","unstructured":"Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X et al. (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345\u20133353.","journal-title":"Blood"},{"key":"BFonc2010554_CR5","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1101\/gad.7.10.2048","volume":"7","author":"T Czerny","year":"1993","unstructured":"Czerny T, Schaffner G, Busslinger M . (1993). DNA sequence recognition by Pax proteins: bipartite structure of the paired domain and its binding site. Genes Dev 7: 2048\u20132061.","journal-title":"Genes Dev"},{"key":"BFonc2010554_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/bies.20089","volume":"26","author":"G Dellaire","year":"2004","unstructured":"Dellaire G, Bazett-Jones DP . (2004). PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 26: 963\u2013977.","journal-title":"Bioessays"},{"key":"BFonc2010554_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0092-8674(94)90340-9","volume":"76","author":"JA Dyck","year":"1994","unstructured":"Dyck JA, Maul GG, Miller Jr WH, Chen JD, Kakizuka A, Evans RM . (1994). A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76: 333\u2013343.","journal-title":"Cell"},{"key":"BFonc2010554_CR8","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1038\/leu.2009.135","volume":"23","author":"J Familiades","year":"2009","unstructured":"Familiades J, Bousquet M, Lafage-Pochitaloff M, Bene MC, Beldjord K, De Vos J et al. (2009). PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia 23: 1989\u20131998.","journal-title":"Leukemia"},{"key":"BFonc2010554_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1158\/0008-5472.CAN-07-2778","volume":"68","author":"G Fazio","year":"2008","unstructured":"Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G . (2008). PAX5\/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res 68: 181\u2013189.","journal-title":"Cancer Res"},{"key":"BFonc2010554_CR10","doi-asserted-by":"publisher","first-page":"24420","DOI":"10.1074\/jbc.M802217200","volume":"283","author":"F Hayakawa","year":"2008","unstructured":"Hayakawa F, Abe A, Kitabayashi I, Pandolfi PP, Naoe T . (2008). Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J Biol Chem 283: 24420\u201324425.","journal-title":"J Biol Chem"},{"key":"BFonc2010554_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1535-6108(04)00082-0","volume":"5","author":"F Hayakawa","year":"2004","unstructured":"Hayakawa F, Privalsky ML . (2004). Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5: 389\u2013401.","journal-title":"Cancer Cell"},{"key":"BFonc2010554_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1189\/jlb.0603389","volume":"75","author":"F Hayakawa","year":"2004","unstructured":"Hayakawa F, Towatari M, Ozawa Y, Tomita A, Privalsky ML, Saito H . (2004). Functional regulation of GATA-2 by acetylation. J Leukoc Biol 75: 529\u2013540.","journal-title":"J Leukoc Biol"},{"key":"BFonc2010554_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1101\/gad.1396206","volume":"20","author":"ML Holmes","year":"2006","unstructured":"Holmes ML, Carotta S, Corcoran LM, Nutt SL . (2006). Repression of Flt3 by Pax5 is crucial for B-cell lineage commitment. Genes Dev 20: 933\u2013938.","journal-title":"Genes Dev"},{"key":"BFonc2010554_CR14","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1182\/blood.V88.11.4110.4110","volume":"88","author":"S Iida","year":"1996","unstructured":"Iida S, Rao PH, Nallasivam P, Hibshoosh H, Butler M, Louie DC et al. (1996). The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 88: 4110\u20134117.","journal-title":"Blood"},{"key":"BFonc2010554_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1083\/jcb.147.2.221","volume":"147","author":"AM Ishov","year":"1999","unstructured":"Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T et al. (1999). PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147: 221\u2013234.","journal-title":"J Cell Biol"},{"key":"BFonc2010554_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccr.2010.06.003","volume":"18","author":"M Jeanne","year":"2010","unstructured":"Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S et al. (2010). PML\/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18: 88\u201398.","journal-title":"Cancer Cell"},{"key":"BFonc2010554_CR17","doi-asserted-by":"publisher","first-page":"11921","DOI":"10.1073\/pnas.0711039105","volume":"105","author":"N Kawamata","year":"2008","unstructured":"Kawamata N, Ogawa S, Zimmermann M, Niebuhr B, Stocking C, Sanada M et al. (2008). Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci USA 105: 11921\u201311926.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2010554_CR18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S1097-2765(01)00257-X","volume":"7","author":"MM Khan","year":"2001","unstructured":"Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Shinagawa T et al. (2001). Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Mol Cell 7: 1233\u20131243.","journal-title":"Mol Cell"},{"key":"BFonc2010554_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/j.1460-2075.1994.tb06356.x","volume":"13","author":"MH Koken","year":"1994","unstructured":"Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N et al. (1994). The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. Embo J 13: 1073\u20131083.","journal-title":"Embo J"},{"key":"BFonc2010554_CR20","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1128\/MCB.12.6.2662","volume":"12","author":"Z Kozmik","year":"1992","unstructured":"Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M . (1992). The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol 12: 2662\u20132672.","journal-title":"Mol Cell Biol"},{"key":"BFonc2010554_CR21","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1093\/nar\/gkg785","volume":"31","author":"H Maier","year":"2003","unstructured":"Maier H, Ostraat R, Parenti S, Fitzsimmons D, Abraham LJ, Garvie CW et al. (2003). Requirements for selective recruitment of Ets proteins and activation of mb-1\/Ig-alpha gene transcription by Pax-5 (BSAP). Nucleic Acids Res 31: 5483\u20135489.","journal-title":"Nucleic Acids Res"},{"key":"BFonc2010554_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.1067518","volume":"297","author":"I Mikkola","year":"2002","unstructured":"Mikkola I, Heavey B, Horcher M, Busslinger M . (2002). Reversion of B cell commitment upon loss of Pax5 expression. Science 297: 110\u2013113.","journal-title":"Science"},{"key":"BFonc2010554_CR23","first-page":"3893","volume":"62","author":"WH Miller Jr","year":"2002","unstructured":"Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S . (2002). Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893\u20133903.","journal-title":"Cancer Res"},{"key":"BFonc2010554_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1006\/smim.1998.0115","volume":"10","author":"AM Morrison","year":"1998","unstructured":"Morrison AM, Nutt SL, Thevenin C, Rolink A, Busslinger M . (1998). Loss- and gain-of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation. Semin Immunol 10: 133\u2013142.","journal-title":"Semin Immunol"},{"key":"BFonc2010554_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/emboj\/17.1.61","volume":"17","author":"S Muller","year":"1998","unstructured":"Muller S, Matunis MJ, Dejean A . (1998). Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. Embo J 17: 61\u201370.","journal-title":"Embo J"},{"key":"BFonc2010554_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"CG Mullighan","year":"2007","unstructured":"Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. (2007). Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446: 758\u2013764.","journal-title":"Nature"},{"key":"BFonc2010554_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/leu.2008.306","volume":"23","author":"K Nebral","year":"2009","unstructured":"Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA et al. (2009). Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23: 134\u2013143.","journal-title":"Leukemia"},{"key":"BFonc2010554_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2141.2007.06731.x","volume":"139","author":"K Nebral","year":"2007","unstructured":"Nebral K, Konig M, Harder L, Siebert R, Haas OA, Strehl S . (2007). Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia. Br J Haematol 139: 269\u2013274.","journal-title":"Br J Haematol"},{"key":"BFonc2010554_CR29","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1182\/blood.V94.10.3315.422k16_3315_3324","volume":"94","author":"C Niu","year":"1999","unstructured":"Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS et al. (1999). Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94: 3315\u20133324.","journal-title":"Blood"},{"key":"BFonc2010554_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/08830180109056723","volume":"20","author":"SL Nutt","year":"2001","unstructured":"Nutt SL, Eberhard D, Horcher M, Rolink AG, Busslinger M . (2001). Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis. Int Rev Immunol 20: 65\u201382.","journal-title":"Int Rev Immunol"},{"key":"BFonc2010554_CR31","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1093\/emboj\/17.8.2319","volume":"17","author":"SL Nutt","year":"1998","unstructured":"Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M . (1998). Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J 17: 2319\u20132333.","journal-title":"EMBO J"},{"key":"BFonc2010554_CR32","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1182\/blood-2002-10-3305","volume":"101","author":"S Rivella","year":"2003","unstructured":"Rivella S, May C, Chadburn A, Riviere I, Sadelain M . (2003). A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 101: 2932\u20132939.","journal-title":"Blood"},{"key":"BFonc2010554_CR33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1074-7613(02)00418-1","volume":"17","author":"M Schebesta","year":"2002","unstructured":"Schebesta M, Pfeffer PL, Busslinger M . (2002). Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity 17: 473\u2013485.","journal-title":"Immunity"},{"key":"BFonc2010554_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1074-7613(02)00472-7","volume":"17","author":"A Souabni","year":"2002","unstructured":"Souabni A, Cobaleda C, Schebesta M, Busslinger M . (2002). Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity 17: 781\u2013793.","journal-title":"Immunity"},{"key":"BFonc2010554_CR35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1126\/science.279.5356.1547","volume":"279","author":"ZG Wang","year":"1998","unstructured":"Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C et al. (1998a). Role of PML in cell growth and the retinoic acid pathway. Science 279: 1547\u20131551.","journal-title":"Science"},{"key":"BFonc2010554_CR36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/3073","volume":"20","author":"ZG Wang","year":"1998","unstructured":"Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R et al. (1998b). PML is essential for multiple apoptotic pathways. Nat Genet 20: 266\u2013272.","journal-title":"Nat Genet"},{"key":"BFonc2010554_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0092-8674(94)90341-7","volume":"76","author":"K Weis","year":"1994","unstructured":"Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M et al. (1994). Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76: 345\u2013356.","journal-title":"Cell"},{"key":"BFonc2010554_CR38","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1128\/MCB.21.7.2259-2268.2001","volume":"21","author":"WS Wu","year":"2001","unstructured":"Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, Roth S et al. (2001). The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 21: 2259\u20132268.","journal-title":"Mol Cell Biol"},{"key":"BFonc2010554_CR39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/ncb869","volume":"4","author":"S Yang","year":"2002","unstructured":"Yang S, Kuo C, Bisi JE, Kim MK . (2002). PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1\/Chk2. Nat Cell Biol 4: 865\u2013870.","journal-title":"Nat Cell Biol"},{"key":"BFonc2010554_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1126\/science.1183424","volume":"328","author":"XW Zhang","year":"2010","unstructured":"Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB et al. (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328: 240\u2013243.","journal-title":"Science"},{"key":"BFonc2010554_CR41","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/blood.V95.9.2748.009k31a_2748_2752","volume":"95","author":"S Zhong","year":"2000","unstructured":"Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP . (2000a). Role of SUMO-1-modified PML in nuclear body formation. Blood 95: 2748\u20132752.","journal-title":"Blood"},{"key":"BFonc2010554_CR42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1084\/jem.191.4.631","volume":"191","author":"S Zhong","year":"2000","unstructured":"Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D, Pandolfi PP . (2000b). Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med 191: 631\u2013640.","journal-title":"J Exp Med"},{"key":"BFonc2010554_CR43","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1073\/pnas.94.8.3978","volume":"94","author":"J Zhu","year":"1997","unstructured":"Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY et al. (1997). Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94: 3978\u20133983.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2010554.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2010554","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2010554.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T17:14:15Z","timestamp":1647882855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2010554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,10]]},"references-count":43,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2011,4,14]]}},"alternative-id":["BFonc2010554"],"URL":"https:\/\/doi.org\/10.1038\/onc.2010.554","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,10]]},"assertion":[{"value":"5 February 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Naoe received research funding from Kyowa Hakko Kirin Co., Ltd, Wyeth, and Chugai Pharmaceutical Co., Ltd. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}